Contact Us: 1-518-583-0095 
We’re Hiring… Join Our Team!
This is the first clinical trial to investigate CPD in multiple myeloma. Results suggest that the regimen is a well-tolerated and highly active combination for patients with relapsed/refractory multiple myeloma.
Continue readingCORE Science Solutions (CSS) Consortia, the Academic Gastrointestinal Cancer Consortium (AGICC) and Academic Myeloma Consortium (AMyC) will have a presence at the 2012 ASCO meeting June 1-4 in Chicago, IL.
Continue readingThe Academic Myeloma Consortium (AMyC) was present at the December 2011 ASH meeting. The Consortium is part of the CORE Science Solutions (CSS) group of Consortia focused on collaborating with pharmaceutical and biotech companies on the development of drugs to treat myeloma. CSS is part of the Criterium Inc. group of companies.
Continue readingAptium Oncology, a consulting and management company for cancer centers, is putting together a network of investigators specifically focused on myeloma and related cancers. The Aptium Oncology Myeloma Consortium (AMyC) is modeled after Aptium’s GI Cancer Consortium, a group launched in 2008 to focus on gastrointestinal cancers.
Continue readingAptium Oncology, Inc. announced the launch of Aptium Oncology Myeloma Consortium (AMyC), a broad-based collaboration that brings together renowned investigators to work with pharmaceutical sponsors to advance clinical and translational research in myeloma and related cancers.
Continue readingCriterium, Inc., a full-service, global CRO, is pleased to announce the acquisition of the former Aptium Oncology’s CORE Science Solutions (CSS) Cancer Consortium Groups consisting of AGICC and AMyC as the newest members of Criterium’s Pharma services companies. Criterium is proud to include AGICC and AMyC, two academic cancer research consortia in its family of companies. Important and well-known institutions and investigators are actively collaborating as part of the consortia.
Continue readingDr. Lawrence Leichman, Director of the Aptium Oncology GI Cancer Consortium (AGICC), presented two posters at the ASCO-NCI-EORTC Annual Meeting held in Hollywood, Florida October 17-18, 2010.
The posters are the first publications from the AGICC trials. The first poster, titled ‘DNA Repair and Apoptosis,’ was authored by Dr. Leichman and members of the Consortium. The second poster pertains to a Phase II study of a combination compound for advanced colorectal cancer.
Continue readingAptium Oncology’s Research Department featured two consortia at the recent ASCO 2010 Annual Meeting in Chicago which was aptly themed ‘Advancing Quality through Innovation.’ More than 30,000 cancer specialists from around the world gather at this premier meeting annually to discuss the latest innovations in research, quality, practice and technology in cancer.
Continue readingJoin us for our Myeloma and GI Cancer Consortia Reception
Friday, June 4, 2010 6:30 – 8:30 pm
Affinia Chicago • C-View – Rooftop Lounge
166 East Superior Street
Chicago, IL 60611
Please RSVP by Friday, May 21 to Rhonda Hopkins at rhopkins@aptiumoncology.com.
Bus Route from the Convention Center: Gate 3 Route 6
Network with our investigators. Visit our booth #22036.